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Abstract (286 words) 
Introduction 
Tumor mutational burden (TMB) is a quantitative assessment of the number of somatic 
mutations within a tumor genome. Immunotherapy benefit has been associated with TMB 
assessed by whole exome sequencing (wesTMB) and by gene panel sequencing 
(psTMB). The initiatives of Quality in Pathology (QuIP) and Friends of Cancer Research 
(FoCR) have jointly addressed the need for harmonization between TMB testing options in 
tissues. This QuIP study identifies critical sources of variation in psTMB assessment. 
Methods 
Twenty samples from three tumor types (LUAD, HNSC, COAD) with available WES data 
were analyzed for psTMB, using six panels across 15 testing centers. Inter-laboratory and 
inter-platform variation including agreement on variant calling and TMB classification were 
investigated. Bridging factors to transform psTMB to wesTMB values were empirically 
derived. The impact of germline filtering was evaluated. 
Results 
Sixteen samples demonstrated low interlaboratory and interpanel psTMB variation with 
87.7% of pairwise comparisons showing a Spearman’s ρ>0.6. A wesTMB cutpoint of 199 
missense mutations projected to psTMB cutpoints between 7.8 and 12.6 muts/Mbp; the 
corresponding psTMB and wesTMB classifications agreed in 74.9% of cases. For three-
tier classification with cutpoints of 100 and 300 mutations, agreement was observed in 
76.7%, weak misclassification in 21.8%, and strong misclassification in 1.5% of cases. 
Confounders of psTMB estimation included fixation artifacts, DNA input, sequencing 
depth, genome coverage, and variant allele frequency cutpoints. 
Conclusions 
This study provides real-world evidence that all evaluated panels can be used to estimate 
TMB in a routine diagnostic setting and identifies important parameters for reliable tissue 
TMB assessment that require careful control. As complex/composite biomarkers beyond 
TMB are likely playing an increasing role in therapy prediction, the efforts by QuIP and 
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Introduction 
Immune checkpoint inhibitors (ICIs) have greatly expanded therapeutic options in 
oncology.1 While many clinical trials have shown strong clinical responses across various 
tumor types, evidence is increasing that even in generally responsive tumor entities many 
tumors are resistant at baseline or develop resistance to ICIs, e.g., by immunoediting.2 
Moreover, adverse events associated with ICIs have been noted, particularly with 
combinatorial regimens that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 
in addition to programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-
L1).3 Collectively, these observations argue for a sophisticated biomarker approach that 
reflects the interplay between the host’s immune system and the cancer cells and is able 
to reliably separate likely responders from nonresponders. 
 
To date, two predictive ICI-specific biomarkers have been approved in certain cancer 
types: (i) PD-L1, assessed by immunohistochemistry (IHC) with a wide range of different 
scoring systems and cutpoints depending on cancer type-specific trial results, and (ii) high-
level microsatellite instability (MSI-H) or mismatch repair deficiency, assessed by either 
polymerase chain reaction or IHC.4,5 Whereas the former approach measures a 
continuous variable that serves as an approximation for T-cell anergy or tumor cells 
escaping immune response, the latter identifies a subgroup of cancers with a high 
mutational burden and thus increased neoantigen load, which likely results in a higher 




However, many cancer types, including non-small cell lung cancer (NSCLC), do not harbor 
deleterious mutations in one of the DNA mismatch repair genes but show increased tumor 
mutational burden (TMB) associated with higher loads of neoantigens which is caused by 
DNA damage through external noxae (e.g., UV light, smoking) or deleterious mutations 
affecting other DNA repair genes.6 
 
Although clinical trials assessing the utility of TMB prospectively are ongoing, many 
retrospective analyses of individual patient cohorts and clinical trials have demonstrated 
that TMB can be successfully used for patient stratification. Initial seminal studies 
employed whole exome sequencing (WES) to measure TMB.7-10 Because this approach 
has several limitations, including sample requirements, necessity for concurrent germline 
sequencing, extensive laboratory capacity for diagnostic application, and economic 
constraints in consideration of a diagnostic outreach setting, gene panels were designed 
and used to estimate TMB values, primarily in formalin-fixed and paraffin-embedded 
(FFPE) tissue and, more recently, in cell-free circulating tumor DNA.11-13 Such assays 
have been successfully used under controlled trial conditions or at specific academic 
cancer centers. However, a detailed evaluation of the overall performance of commercially 
available sequencing panels that can be used as laboratory-developed tests (LDTs) as 
well as of the parameters affecting its diagnostic applicability is missing. 
To address this important issue, we present the results of the multi-institutional Quality in 
Pathology (QuIP) study on a comparative assessment of TMB estimated by gene panel 
sequencing (psTMB) from 11 different institutes of pathology and four industrial 
laboratories. Analyzing 20 different FFPE cancer samples from routine diagnostics that 
reflect the full continuum of TMB, as measured by WES (wesTMB), provides real-world 
data on six different targeted gene panels designed for TMB estimation: Oncomine Tumor 
8 
 
Mutational Load Assay (OTML; Thermo Fisher Scientific, Waltham, MA), QIAseq TMB 
panel (QIAseq; QIAGEN GmbH, Hilden, Germany), NEOplus RUO assay (NEOplus; NEO 
New Oncology, Cologne, Germany), TruSight Oncology 500 panel (TSO500; Illumina, San 
Diego, CA), a custom-designed academic panel (ACADEMIC; Agilent, Santa Clara, CA), 
and the FoundationOne assay (F1; Foundation Medicine, Cambridge, MA). Together with 
the efforts led by the Friends of Cancer Research (FoCR),14 this study sets the basis for 
harmonization of panel-based TMB measurement and supports implementation of TMB in 
routine diagnostic laboratories. 
Materials and Methods 
Samples 
All patients provided written informed consent under an institutional review board-
approved protocol, and the study was conducted in accordance with the Declaration of 
Helsinki. FFPE tissue specimens of 10 lung adenocarcinoma (LUAD), seven head and 
neck squamous cell carcinoma (HNSC), and three colon adenocarcinoma (COAD) were 
prepared and diagnosed at the Institute of Pathology Heidelberg, Germany. See Suppl. 1 
for further detailed sample information. Only one block per tumor was selected and 
consecutive sections were used for DNA extraction by the different laboratories. Tumor 
content was controlled using HE stained slides on the first and last section to ensure 
homogeneity throughout the slices.  
 
Library Preparation and Sequencing 
Protocols for the six applied panel-sequencing approaches (OTML, QIAseq, NEOplus, 
TSO500, ACADEMIC, and F1), as well as for WES, are detailed in the Supplementary 
Appendix (Suppl. 2). All assays were performed according to the manufacturers’ protocols 




Data Analysis and Visualization 
Data analysis and visualization were performed using the statistical programming 
language R.15 Levels of psTMB were visualized as boxplots and as heatmaps including 
hierarchical clustering of experiments (Manhattan distance, average linkage clustering). 
Spearman correlations (ρ) and Pearson correlations (R) of psTMB were calculated 
between pairs of experiments, clustered (Euclidean distance, average linkage clustering), 
and visualized as heatmaps. Error bars were plotted using the function plotCI from the R 
package gplots. Violin plots were generated using the R package vioplot. 
 
Linear models without intercept were fitted to psTMB levels with wesTMB levels. 
Measurement of psTMB is influenced by different factors. Although misclassification of 
germline mutations as somatic mutations is independent of the TMB level, other factors, 
including the subsampling error caused by interrogation of only a limited part of the coding 
sequence (CDS), increase with a higher TMB.16 Because the exact shape of the 
mathematical dependence of the TMB error on the level of the TMB is not known, linear 
models were fitted in two different ways: (i) standard linear regression (least square 
regression, LS) corresponding to constant error contributions, and (ii) weighted linear 
regression (weighted least squares, WLS) with weights equal to the reciprocal of TMB 
taking into account heteroscedasticity. The shape of the weights used in the WLS model 
reflects the mathematical law for the variation of psTMB that we recently uncovered and 






In this study (Fig. 1), FFPE tissue samples of 20 tumors (Suppl. 1) with existing matched 
WES data were analyzed using four commercial panel-sequencing TMB assays (Suppl. 2). 
Each assay was run by four different pathology laboratories as well as by a reference 
laboratory of the panel provider on all samples. Additionally, three pathology laboratories 
tested the ACADEMIC assay, and all samples were analyzed using the F1 assay. The 
analyzed study cohort was selected to represent the full spectrum of TMB values as 
characterized by The Cancer Genome Atlas for LUAD, HNSC, and COAD, but has a 
higher proportion of tumors with an intermediate TMB (100 to 300 mutations, Suppl. 3). In 
total, panel sequencing and psTMB measurement was successful in 97.3% (467 of 480) of 
the performed analyses. 
 
TMB Levels and Correlations 
Measurements of psTMB in the 20 tumor-tissue samples ranged between 0 and 244 
mutations per megabase pair (muts/Mbp) with a median of 9.2 muts/Mbp (Fig. 2A). With 
respect to interlaboratory and interpanel variance, four of the tumor samples (T4, T7, T13, 
and T15) stood out by showing a larger interquartile range of psTMB compared with the 
remaining samples. This was mainly due to unfavorable preanalytic quality parameters 
(degraded DNA or low tumor cellularity, Fig. 2A). Two samples (T4 and T15) showed a 
large interlaboratory variance of psTMB when each of the panels was analyzed separately, 
whereas this was not the case for the two other tumor samples (T7 and T13), where 
interpanel variance was an important confounder (Suppl. 4). 
In a heatmap including hierarchical clustering of the psTMB levels, data readouts based 
on the same sequencing panel often clustered together, indicating independence from the 
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operating laboratory (Fig. 2B). Between most of the sequencing results, moderate to 
strong pairwise correlations of psTMB measurements were observed: of all pairwise 
Spearman correlations, 65.9% were ≥0.7, 87.7% were ≥0.6, and 95.7% were ≥0.5 
(Fig. 2C). In the study cohort, the strength of Pearson correlations was dependent on the 
inclusion or exclusion of a single sample (T16, POLE-mutated colorectal carcinoma) that 
had a very high TMB (>100 muts/Mbp, Suppl. 5). Hence, the Spearman correlation was 
more suitable approach for the measurement of the psTMB correlations than the Pearson 
method. 
 
Bridging from psTMB to wesTMB 
Linear regression models were fitted for bridging from psTMB to wesTMB (Fig. 3). To this 
end, we performed standard linear regression (LS), but also weighted linear regression 
(WLS, see Materials and Methods for details) for each of the panels tested in the study. 
Bridging factors (BFs) for transformation of psTMB to wesTMB were calculated as 
reciprocals of the regression slopes (Suppl. 6). For most of the assays, the BF determined 
by WLS was very close to the BF determined by LS. However, for the ACADEMIC assay, 
the WLS BF was slightly lower than the LS BF (17.7 vs. 19.8), whereas it was considerably 
lower for the QIAseq assay (15.8 vs. 25.6). 
 
A clinically relevant psTMB cutpoint of 10 muts/Mbp in NSCLC was established in the 
CheckMate 568 study using the F1 panel, evaluated in the CheckMate 227 study, and 
bridged to a wesTMB cutpoint of 199 mutations using data from the CheckMate 026 
study.17-19 Based on these findings, we calculated psTMB cutpoints corresponding to 199 
mutations for each of the investigated assays (Suppl. 6). For most of the psTMB assays, 
the calculated cutpoints were consistently in the range of 9.4 to 11.5 muts/Mbp. There 
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were two exceptions: considerably different cutpoints were obtained for the OTML assay 
(LS: 7.8 muts/Mbp, WLS: 7.9 muts/Mbp) and for the QIAseq assay (LS: 7.8 muts/Mbp, 
WLS: 12.6 muts/Mbp). 
 
TMB Classification 
Next, we evaluated a two-tier in comparison to a three-tier system for TMB classification 
(Fig. 4) following a recent indication to improve the misclassification ratio. For the two-tier 
approach, a dichotomization into “low TMB” and “high TMB” was conducted using a 
wesTMB cutpoint of 199 mutations. The three-tier classification classified TMB as “low” 
(<100 mutations), “intermediate” (100 to 300 mutations) and “high” (≥300 mutations). 
Classification with alternative cutpoints (150 and 250 mutations) is shown in Suppl. 7. For 
each of the panel sequencing platforms, psTMB values were converted to wesTMB values 
using the BFs obtained by WLS regression. Altogether (20 samples × 24 experiments), we 
observed an agreement between psTMB and wesTMB classifications in 74.9% of the 
cases using the two-tier approach. For the three-tier approach, a “strong misclassification” 
was defined by a high TMB tumor classified as low TMB or vice versa (difference spanning 
two tiers), whereas a misclassification by a single tier (e.g., intermediate TMB to low TMB) 
was termed “weak misclassification.” Here, we observed an agreement in 76.7% of cases, 
compared with a weak and strong misclassification in 21.8% and 1.5% of the cases, 
respectively. Of note, strong misclassification occurred only for a single tumor sample (T4) 
that was classified as low TMB by WES but as high TMB in seven psTMB assays and was 
not analyzable in five psTMB approaches. Assessment of this tumor (LUAD) was priori 




TMB classifications using BFs determined either by WLS or LS regression were similar, as 
LS regression resulted in 74.3% agreement for two-tier classification as well as 75.0% 
agreement, 23.1% weak misclassifications, and 1.9% strong misclassifications for three 
tier classification. 
 
Interlaboratory comparison of the identified variants 
In-depth analysis of called variants included in the calculation of TMB identified key factors 
that influence precise psTMB estimation from FFPE tissue (Fig. 5). A sequencing 
approach without an application for PCR duplicate removal, known as deduplication, has a 
higher probability of erroneous calling of C>T/G>A fixation artifacts and subsequent 
overestimation of psTMB, especially in highly fragmented, low-quality DNA samples. 
Methods for deduplication include specialized software solutions as well as the use of 
unique molecular identifiers (UMIs, or molecular barcodes). 
False-positive variants in the generated data set were identified by a side-to-side 
comparison of all variants identified by the different laboratories using the same panel. 
Variants were classified into non-reproducible variants (detected by a single laboratory), 
partially reproducible variants (detected by more than one laboratory, but not by all 
laboratories) and fully reproducible variants (detected by all laboratories). Variant allele 
frequencies (VAFs) were considerably lower for variants with low degrees of 
interlaboratory reproducibility and many of the non-reproducible variants had VAFs close 
to the VAF cutpoint (Fig. 5A). Thus, low frequency variants close to the VAF cutpoint 
contributed considerably to psTMB variation. To minimize the rate of false-positive calls, 
specific thresholds for VAF were used for each panel according to the assay provider: VAF 
≥10% was applied for the OTML and NEOplus panels and VAF ≥5% for the remaining 
panels. The number of non-reproducible variants was considerably higher for the OTML 
14 
 
assay (3497 variants), which did not include deduplication, compared with the other 
assays (QIAseq: 1055; NEOplus: 94; TSO500: 70; ACADEMIC: 691). In addition, as 
illustrated in Fig. 5B, the ratio of C>T/G>A transitions was significantly higher for non-
reproducible variants (red pie charts) detected by the OTML panel (86%) compared with 
the other panels (22%–42%), and also compared with the ratio of C>T/G>A of variants that 
were detected by all laboratories (gray pie charts). These data identify paraffin fixation 
artifacts and resulting C>T/G>A transitions as important parameters contributing to false-
positive variant detection for assays that do not employ deduplication. 
 
False-negative calls (defined here as mutations called by all but one laboratory) can be 
connected to insufficient depth of coverage at the respective positions. Because the 
pipelines for capture-based fragment libraries typically include deduplication and UMI 
filtering, the depth of coverage directly correlates with the amount of DNA input, as shown 
representatively for the TSO500 panel in Fig. 5C. Here, the median exon coverage that 
could be analyzed was significantly higher in lab 1 using 80 ng as DNA input compared 
with 40 ng that was used for the other TSO500 approaches (labs 2, 7, 11, and Illumina). 
Further, the amount of DNA input had a strong impact on the average size of the covered 
sequencing region (Fig. 5C, middle). While the maximum covered coding region size of 
1.28 Mbp was reached for all samples using 80 ng (lab 1), lower DNA input resulted in 
significant (p < 0.01) lower covered coding region sizes, which were larger than 1.0 Mbp in 
35% to 100% of the analyzed samples. To enhance specificity, only mutations with 
minimum coverage of 100x were included in the psTMB calculation. Therefore, and 
connected to the lower coverage, we observed a higher rate of false-negative variants in 
analyses using 40 ng DNA (labs 2, 7, 11, and Illumina) compared with 80 ng (Fig. 5C, 
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right). Similar findings were seen for 100 ng vs. 200 ng DNA input using the NEOplus 
assay (data not shown). 
 
Germline Mutation Filtering 
Germline mutation filtering is an important step in the calculation of psTMB because only 
the tumor’s somatic mutations are relevant for recognition by the immune system. In the 
absence of sequencing of paired-normal tissue/blood samples in most diagnostic 
scenarios, germline mutation filtering needs to be performed in silico. For all assays 
evaluated in the current TMB harmonization study, the bioinformatic pipelines include a 
step of negative filtering for entries in single nucleotide polymorphism (SNP) databases 
such as gnomAD, ExAC, and dbSNP. Additionally, some of the pipelines include further 
steps; for example, filtering by algorithms specifically designed to distinguish somatic vs. 
germline mutations such as somatic-germline zygosity (SGZ) or filtering with respect to the 
mutations detected by panel sequencing of reference cohorts of normal samples (e.g., 
NEOplus, ACADEMIC panel).20 We evaluated the performance of filtering using SNP 
databases for the LUAD samples (n = 10; Suppl. 8). Variants detected by WES in matched 
blood samples were used as a reference. The sensitivity for classifying mutations as 
somatic was 87%, 90%, and 79%, with corresponding positive predictive values (PPVs) of 
90%, 90%, and 91% when using gnomAD, ExAC, and dbSNP for filtering (pooled analysis 
of the 10 tumor samples). Filtering out only common SNPs (minor allele frequency [MAF] > 
0.001 in gnomAD) increased sensitivity to 98%, but decreased PPV to 81%. 
 
While germline mutation filtering using gnomAD and ExAC performed well, rs-filtering 
(dbSNP) appeared to be too stringent. Restriction of filtering to common SNPs 
considerably decreased the number of false negatives, but increased the number of false 
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positives. Additional filters that are implemented in the panel-specific bioinformatic 
pipelines, such as SGZ algorithm or the TSO500 “proxy filter” (Suppl. 9), can further 





Tumor vs. matched blood WES was used in many initial clinical I-O studies and may be 
considered a reference standard for TMB assessment. However, clinical implementation of 
WES-based TMB assessment may be impractical, considering the financial costs and the 
limited availability of appropriately-preserved samples or quality DNA, and matched normal 
samples for germline sequencing. Gene panel assays offer a number of economical and 
practical advantages for clinical assessment of patient samples, including increased 
sequencing depth, in silico germline subtraction (negating the requirement for matched 
samples), and concurrent evaluation of actionable mutations. 
The QuIP study provides a thorough analysis of real-world performances of six select TMB 
panels. Using real-world diagnostic FFPE samples, which included different types of 
challenging cases with poor DNA quality, heavy fixation artifacts, or low tumor cellularity, 
our results demonstrate that in principle all assays tested in this study were able to 
estimate TMB values and could be applied in a diagnostic setting. 
The effect of panel size and coverage on the accuracy of psTMB assessment have been 
previously studied using in silico simulations of gene panels derived from WES data.16,21 
The gene panels used in the LDTs covered at least 1 Mbp of the CDS, which was shown 
to be essential for valid panel-based TMB assessment.21 However, even with these large 
panels, variability of the TMB score can be expected because psTMB measurement has a 
probabilistic nature: the overall TMB is extrapolated by investigating only a fraction (about 
1/30) of the exome. Simulating five commercial panels in WES data, only 17%-28% of 
additional error occurred on top of the unavoidable probabilistic error demonstrating that 
sufficient panel size is more critical than the particular localization of the panel in the 
exome.16 
There is a multitude of other wet-lab parameters, ranging from biological factors (e.g., 
tumor heterogeneity) and preanalytics (e.g., DNA quality) to sequencing (e.g., coverage) 
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as well as bioinformatics parameters (e.g., germline subtraction) that can influence TMB 
scores.22-25 Hence, as expected, absolute TMB values slightly varied. This scenario is not 
unknown to pathology in general and immune oncology response prediction in particular: 
just as for TMB, the established PD-L1 IHC assay for NSCLC quantifies a continuous 
variable in tumor cells ranging from 0% to 100% PD-L1 expressing cells, and several 
parameters, such as tumor heterogeneity and fixation, are known to influence PD-L1 
scores.4,26 Just as with PD-L1, for clinical purposes TMB as a continuous measure must 
be categorized. In our approach we stratified samples into one of three groups, which 
categorized the continuum of TMB ranging from 0 to >200 muts/Mbp: low, intermediate, 
and high TMB, according to a concept proposed by us recently.16 In contrast to a two-tier 
system with one defined cutoff, this concept allows for a definition of a certain 
“intermediate” grey zone of TMB measurements in an area around the currently proposed 
clinical cutpoint. Using cutpoints of 100 mutations (corresponding to approximately 5 
muts/Mbp) and 300 mutations (corresponding to approximately 15 muts/Mbp), strong 
misclassifications occurred only for a single tumor sample (T4), a case that was 
particularly challenging because of poor DNA quality, which would justify to decline 
analysis in a clinical setting. Misclassification of other highly degraded samples (T12 and 
T19) or critical cases with a low tumor-cell content (T15), MSI-H status (T13 and T15), or a 
loss-of-function mutation in POLE (T16) was prevented using the three-tier system instead 
of the two-tier system. 
We observed an overall low influence of the specific laboratory performing the analysis; 
data generated by the industrial partners for their specific panel were in the range of the 
respective TMB scores determined by the hospital laboratories. Moreover, we found that 
most panels showed moderate to strong (ρ = 0.64 to 0.84) correlations with TMB 




Our study also showed that germline subtraction using bioinformatic pipelines can be used 
to identify likely somatic variants in the probabilistic setting of psTMB measurement. 
However, as shown by us recently, incorrect filtering can influence TMB scores in 
individual cases, and future studies are warranted to further investigate the influence of in 
silico vs. blood-based subtraction of germline events.24,27 As current germline variant 
databases are biased toward e.g. Caucasian populations, ethnicity-related aspects require 
careful analysis in this context. 
We identified assay-independent and assay-specific parameters (Fig. 6) that will require 
careful control when psTMB is implemented in routine diagnostics. Of these, the effects of 
tumor-cell content, DNA input and coverage are most critical in order to prevent the miss 
of mutations which would result in too low psTMB scores. Another important aspect are 
deamination artifacts (C>T transitions) created by formalin fixation, which can be 
diagnostically challenging when left uncontrolled. In this regard DNA amplification during 
panel sequencing can be critical as overamplification of artefacts or additional errors 
during replication can occur leading to false positive mutation calls and subsequently to 
overestimated psTMB scores. This issue can be compensated by setting an appropriate 
limit of detection (LOD) for the allelic frequency and especially by applying in silico and/or 
technical (molecular barcodes) approaches for deduplication (removal of PCR duplicates). 
In the present data set a LOD of 5% in combination with deduplication yielded reliable 
mutation calling, and eventually TMB values. Hybrid-capture based target enrichment was 
favorable in this context. In panels without deduplication, deamination artifacts may be 
controlled by increasing the LOD to e.g. 10%, rendering cases with low tumor cellularity 
challenging due to the impaired sensitivity. Recent reports indicate that the application of 
uracil-DNA glycosylase (UDG), an enzyme selectively digesting uracil-containing nucleic 
20 
 
acids, can reduce deamination artifacts, when assessing TMB in FFPE samples using 
assays without a deduplication approach.28-30 However, the effect of this approach was not 
tested in this study.  
 
We also calculated bridging factors to convert psTMB to wesTMB for the assessed panels. 
Although future studies exploring larger sample sets will likely improve this analysis, we 
believe that the data shown here provide a strong and sound basis that will facilitate the 
comparison of TMB values obtained by different panels. 
 
A limitation of our study is the limited number of cases as well as the use of three different 
cancer types. The latter selection was influenced by (i) a case mix that reflects the 
continuum of TMB, (ii) avoiding results bias due to a single cancer type, (iii) tissue 
availability for the entire study and all partners, and (iv) availability of corresponding WES 
data. Since the predictive power of TMB is currently being tested in many immuno-
oncology trials across various cancer types and as our study is primarily aimed at 
investigating the ability of panels to measure TMB, we believe that these points do not 
interfere with our results and conclusions. 
In summary, the QuIP study provides real-world evidence that all panels tested in this 
study can be used to estimate TMB by panel sequencing from FFPE samples in a routine 
diagnostic setting. However, this study has identified a number of critical parameters, 
including sample fixation, DNA input, sequencing depth, genome coverage, and variant 
allele frequency cutpoints, that may confound psTMB estimation and require careful 
control to achieve successful and reliable psTMB analysis. Beyond TMB, in conjunction 
with efforts by FoCR, this study provides a blueprint and framework for the systematic 
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analysis of complex/composite predictive biomarkers, which will likely play an increasing 





We thank all teams of the participating institutions for their contributions, and the QuIP 
team for excellent administration. We also thank the entire team of the Center for 
Molecular Pathology (CMP) at the Institute of Pathology Heidelberg (IPH) for expert 
technical assistance and fruitful discussions. The support of the HIPO program and GPCF 
(both DKFZ) are gratefully acknowledged. Editorial assistance was provided by Stuart 
Rulten, PhD, and Jay Rathi, MA, of Spark Medica Inc., funded by Bristol-Myers Squibb. 
We thank David Fabrizio for fruitful discussions related to this project. We thank Sandra 
Siesing for expert editorial assistance and overall handling of the manuscript. 
 
Conflicts of Interests 
The study was partly sponsored by Bristol-Myers Squibb, Illumina, MSD, FMI, Neo New 
Oncology, QIAGEN, Roche, and Thermo Fisher Scientific. 
 
AS: Advisory board honoraria from: AstraZeneca, Bayer, BMS, Illumina, Novartis, Seattle 
Genomics, Takeda, ThermoFisher. Speaker’s honoraria: AstraZeneca, Bayer, BMS, Illumina, 
MSD, Novartis, Roche, Seattle Genomics, Takeda, ThermoFisher. Research funding: Chugai, 
BMS, Bayer 
VE: personal fees from Thermo Fisher, personal fees from Astra Zeneca 
JB: has nothing to disclose. 
SMB: QuIP, during the conduct of the study. Personal fees from BMS, personal fees from Roche, 
personal fees from Novartis, personal fees from Pfizer, personal fees from Astra Zeneca, personal 
fees from Bayer, non-financial support from Illumina, non-financial support from Janssen 
WD: Stockholding Healthineers. 
NP: has nothing to disclose. 
US: has nothing to disclose. 
MH: has nothing to disclose. 
JA: has nothing to disclose. 
SH: Dr. Herold 
MZ: Grants from F. Hoffmann-La Roche AG, Basel, CH, during the conduct of the study; grants 
from F. Hoffmann-La Roche AG, Basel CH outside the submitted work. 
DK: personal fees from Pfizer Pharma GmbH 
JM: personal fees from BMS, personal fees from  
DMM: has nothing to disclose. 
MSt: has nothing to disclose. 
JA: has nothing to disclose. 
KZ: Dr. Zaoui 
MSch: has nothing to disclose. 
HG: has nothing to disclose. 
DH: personal fees from Bayer, personal fees from BMS, personal fees from Roche 
23 
 
MT: other from MSD, other from BMS 
ME: has nothing to disclose. 
HM: grants from Roche, during the conduct of the study. Grants from Roche, personal fees from 
Roche, outside the submitted work. 
TK: has nothing to disclose. 
RB: Professor Büttner 
PS: grants from QuIP, during the conduct of the study; grants and personal fees from BMS, grants 
and personal fees from MSD, grants and personal fees from Roche, grants and personal fees from 
AstraZeneca, grants and personal fees from Novartis, personal fees from Chugai, personal fees 
from AbbVie, grants from Sanofi-Aventis, personal fees from Ipsen, grants and personal fees from 
Pfizer, grants from Illumina, grants from Thermo Fisher, outside the submitted work. 
ER: has nothing to disclose. 
AJ: other from QuIP GmbH, personal fees and non-financial support from BMS, during the conduct 
of the study. Personal fees and non-financial support from Amgen, personal fees and non-financial 
support from Boehringer Ingelheim, personal fees and non-financial support from Novartis, 
personal fees and non-financial support from Bayer, personal fees and non-financial support from 
Merck Serono, personal fees and non-financial support from Roche Pharma, personal fees and 
non-financial support from Biocartis, personal fees and non-financial support from Merck Sharp 
Dome (MSD), personal fees and non-financial support from ThermoFisher, outside the submitted 
work. 
FH: non-financial support from Illumina, non-financial support from Qiagen, during the conduct of 
the study: Grants, personal fees and non-financial support from Illumina, personal fees and non-
financial support from Qiagen, personal fees from BMS, personal fees from Novartis, personal fees 
from Merck, personal fees from Astra Zeneca, personal fees from Pfizer, personal fees from Bayer, 
outside the submitted work. 
LT: non-financial support from Illumina, Inc, non-financial support from QIAGEN, non-financial 
support from Agilent Technologies, during the conduct of the study. 
WW: personal fees from Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, 
Novartis, Takeda, Amgen, Astellas and grants from Roche, MSD, BMS, Bruker outside the 
submitted work. 
MD: Professor Dietel 
SF: personal fees from Amgen, grants from AstraZeneca, personal fees from Eli Lilly, grants from 
Pfizer, grants from PharmaMar, personal fees from Roche, personal fees from Bayer, outside the 
submitted work. 
GB: Dr. Baretton has nothing to disclose. 
CW: Professor Wickenhauser 
 
Author Contributions 
Conceived and designed the study: MD, RB, SMB, FH, WW, AJ, JM, PS, MH, TK, HM, 
DK, JB, VE, AS  
Provided samples: DH, SF, PS, HG, AS, VE 
Sequenced and analyzed cases: AS, VE, JB, SMB, DK, WD, NP, US, MH, SH, JA, MZ, 
LT, ER, MS, HG, SF, JA, DH, GB, CW, MT, ME, HM, TK, RB, OS, AJ, FH, WW, MD  
Statistical analyses: JB, ER, VE, DK, AS 
Manuscript draft: AS, DK, VE, JB, PS, MD 
24 
 
Contribution to writing: all authors 




Figure 1. Outline of the QuIP TMB harmonization study. In this comparative study, FFPE 
tissue samples from 20 tumors were analyzed using four commercial panel-sequencing 
TMB assays. Each assay was tested by four independent pathology laboratories using all 
20 samples as well as by a reference laboratory of the panel provider. Additionally, all 
samples were analyzed using an “academic” assay in three hospital laboratories, and by 
applying the F1 assay. The study cohort consisted of 20 samples from patients with LUAD 
(n = 10), HNSCC (n = 7), and COAD (n = 3). For all tumors, wesTMB using fresh-frozen 
tumor tissue samples and paired-blood samples was available. ACADEMIC, custom-
designed academic panel; COAD, colon adenocarcinoma; F1, FoundationOne assay; 
FFPE, formalin-fixed and paraffin-embedded; HNSCC, head and neck squamous cell 
carcinoma; LUAD, lung adenocarcinoma; NEOplus, NEOplus RUO assay; OTML, 
Oncomine Tumor Mutational Load Assay; psTMB, TMB assessed by gene panel 
sequencing; QIAseq, QIAseq TMB panel; TMB, tumor mutational burden; TSO500, 
TruSight Oncology 500 panel; WES, whole exome sequencing; wesTMB, TMB assessed 
by WES. 
 
Figure 2. (A) Overview of the generated psTMB estimates with tumors ordered by 
increasing wesTMB levels. Applying a three-tier classification system, four tumors (T1–T4) 
were classified as TMB low (<100 missense mutations), eleven tumors were classified as 
TMB intermediate (100 to 300 missense mutations), and five tumors (T5–T7, T13, and 
T16) were classified as TMB high (≥300 missense mutations). Four samples stood out by 
high interquartile ranges and are marked by red IDs. Preanalytic quality parameters were 
unfavorable for three of these samples (T15: low tumor cellularity; T4 and T13: degraded 
DNA). (B) Heatmap of psTMB levels. Red colors: psTMB level >10 muts/Mbp. Green 
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colors: psTMB level <10 muts/Mbp. White: insufficient DNA quality. (C) Spearman 
correlations between psTMB and wesTMB levels in the study cohort. ACADEMIC, custom-
designed academic panel; F1, FoundationOne assay; muts/Mbp, mutations per megabase 
pair; NEOplus, NEOplus RUO assay; OTML, Oncomine Tumor Mutational Load Assay; 
psTMB, TMB assessed by gene panel sequencing; QIAseq, QIAseq TMB panel; TMB, 
tumor mutational burden; TSO500, TruSight Oncology 500 panel; WES, whole exome 
sequencing; wesTMB, TMB assessed by WES. 
 
Figure 3. Calibration of TMB measured by psTMB against wesTMB. Linear fits using LS 
and WLS regression. (A) Overview plots showing all psTMB and wesTMB measurements. 
(B) Zoom-ins to the intervals [0, 650] of wesTMB and [0, 65] of psTMB. The intercepts in 
the linear regression models were set to zero. ACADEMIC, custom-designed academic 
panel; F1, FoundationOne assay; LS, least squares; muts/Mbp, mutations per megabase 
pair; NEOplus, NEOplus RUO assay; OTML, Oncomine Tumor Mutational Load Assay; 
psTMB, TMB assessed by gene panel sequencing; QIAseq, QIAseq TMB panel; TMB, 
tumor mutational burden; TSO500, TruSight Oncology 500 panel; WES, whole exome 
sequencing; wesTMB, TMB assessed by WES; WLS, weighted least squares. 
 
Figure 4. TMB classification by panel sequencing compared with TMB classification by 
WES. Measurements of psTMB were converted to wesTMB using the bridging factors in 
Suppl. 6. (A) Two-tier classification using the cutpoint of 199 mutations. Misclassifications: 
25.1%. (B) Three-tier classification using the cutpoints of 100 and 300 mutations. 
Red: high TMB; yellow: intermediate TMB; green: low TMB. Strong misclassifications 
(= misclassifications mixing TMB high and TMB low cases): 1.5%. Weak misclassifications 
(= misclassifications mixing intermediate TMB cases with TMB high or TMB low cases): 
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21.8%. ACADEMIC, custom-designed academic panel; F1, FoundationOne assay; 
NEOplus, NEOplus RUO assay; OTML, Oncomine Tumor Mutational Load Assay; psTMB, 
TMB assessed by gene panel sequencing; QIAseq, QIAseq TMB panel; TMB, tumor 
mutational burden; TSO500, TruSight Oncology 500 panel; WES, whole exome 
sequencing; wesTMB, TMB assessed by WES. 
 
Figure 5. Interlaboratory reproducibility of the detected mutations (pooled analysis of 
20 samples). (A) Distribution of VAFs in dependence of the number of laboratories that 
detected the mutation. (B) Mutation type (C>T/G>A or other) of the mutations detected by 
a single lab. (C) Impact on DNA input is representatively shown for the TSO500 panel. 
DNA input: 80 ng (lab 1), 40 ng (labs 2, 7, 11, and Illumina). Left: Median exon coverage 
for each sample; the number on top gives the percentage of cases with a median exon 
coverage of more than 150×. Middle: Covered coding region size for each sample. The 
number on top gives the percentage of cases with a covered coding region of more than 
1.0 Mbp. Right: Coverage of mutations not-called by a single lab (false negatives). 
ACADEMIC, custom-designed academic panel; NEOplus, NEOplus RUO assay; OTML, 
Oncomine Tumor Mutational Load Assay; QIAseq, QIAseq TMB panel; TSO500, TruSight 
Oncology 500 panel; VAF, variant allele frequency. 
 
Figure 6. Schematic representation of assay-independent and assay-specific parameters 
influencing the accuracy of psTMB scores. Lower lane: Four representative samples 
showing the effect of deduplication strategies (#2), insufficient sample material (#3) or low 
tumor purity (#4) on DNA input, coverage, covered coding sequence, variant calling, and 
the resulting psTMB scores. Red arrow pointing down indicates false negative effect. Red 
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arrow pointing up indicates false positive effect. psTMB, TMB assessed by gene panel 
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Suppl. 1. Origin, TCC, and DNA quality of the analyzed tumor tissue samples. COAD, 
colon adenocarcinoma; HNSCC, head and neck squamous cell carcinoma; LUAD, lung 
adenocarcinoma; MSI-H, high-level microsatellite instability; TCC, tumor cell content. 
 
Suppl. 2. Overview of the sequencing panels evaluated for tumor mutational burden 
measurement and detailed methodological information for panel and whole exome 
sequencing approaches. 
 
Suppl. 3. Distribution of tumor mutational burden assessed by whole exome 
sequencing in LUAD, LUSC, HNSCC, and COAD. Data from The Cancer Genome 
Atlas. COAD, colon adenocarcinoma; HNSCC, head and neck squamous cell 
carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. 
 
Suppl. 4. Intra-laboratory variability for each of the tested sequencing panels. Mean 
psTMB with error bar equal to the psTMB SD. Top line: CV. ACADEMIC, custom-
designed academic panel; CV, coefficient of variation; muts/Mbp, mutations per 
megabase pair; NEOplus, NEOplus RUO assay; OTML, Oncomine Tumor Mutational 
Load Assay; psTMB, TMB assessed by gene panel sequencing; QIAseq, QIAseq TMB 
panel; SD, standard deviation; TMB, tumor mutational burden; TSO500, TruSight 
Oncology 500 panel. 
 
Suppl. 5. Inter-laboratory and inter-assay correlations (Pearson R) between levels of 
TMB assessed by gene panel sequencing and TMB assessed by whole exome 
sequencing. (A) Study cohort (n = 20). (B) Study cohort without sample T16 (sample 
with very high TMB, n = 19). ACADEMIC, custom-designed Academic panel; F1, 
FoundationOne assay; NEOplus, NEOplus RUO assay; OTML, Oncomine Tumor 
Mutational Load Assay; QIAseq, QIAseq TMB panel; TMB, tumor mutational burden; 
TSO500, TruSight Oncology 500 panel. 
 
Suppl. 6. Conversion of wesTMB values to psTMB values and vice versa. BF: factor to 
multiply psTMB for conversion to wesTMB. LS: BF from LS. WLS: BF from WLS. 
ACADEMIC, custom-designed academic panel; BF, bridging factor; F1, FoundationOne 
assay; LS, least squares; NEOplus, NEOplus RUO assay; OTML, Oncomine Tumor 
Mutational Load Assay; psTMB, TMB assessed by gene panel sequencing; QIAseq, 
QIAseq TMB panel; TMB, tumor mutational burden; TSO500, TruSight Oncology 500 
panel; wesTMB, TMB assessed by whole exome sequencing; WLS, weighted least 
squares. 
 
Suppl. 7. Three-tier classification using the cutpoints of 150 and 250 mutations. Red: 
high TMB; yellow: intermediate TMB; green: low TMB. Strong misclassifications (i.e., 
misclassifications mixing TMB high and TMB low cases): 5.8%. Weak misclassifications 
(i.e., misclassifications mixing intermediate TMB cases with TMB high or TMB low 
cases): 25.9%. ACADEMIC, custom-designed academic panel; F1, FoundationOne 
assay; NEOplus, NEOplus RUO assay; OTML, Oncomine Tumor Mutational Load 
Assay; QIAseq, QIAseq TMB panel; TMB, tumor mutational burden; TSO500, TruSight 
Oncology 500 panel; WES, whole exome sequencing. 
 
Suppl. 8. Performance of germline filtering for the mutations detected by a panel of 
1.34 Mbp in ten LUAD samples. In silico database filtering is compared with filtering by 
sequencing of paired normal (germline) samples. (A) Sensitivity, specificity, accuracy, 
PPV, and NPV of the classification as somatic mutation in 1516 mutations (pooled 
analysis of ten samples). (B–E) TMB error resulting from false somatic and false 
germline classifications for each of the 10 tumors. MAF, minor allele frequency; 
muts/Mbp, mutations per megabase pair; NPV, negative predictive value; PPV, positive 
predictive value; TMB, tumor mutational burden. 
 
Suppl. 9. As Suppl. 8, but for the germline mutation filtering pipeline developed by 
Illumina for the TSO500 panel. (A) Comparison of the Illumina pipeline with filtering by 
gnomAD, ExAC, and dbSNP. (B) Illumina pipeline, database filtering only. (C) Illumina 
pipeline, database and proxy filtering. MAF, minor allele frequency; muts/Mbp, 
mutations per megabase pair; NPV, negative predictive value; PPV, positive predictive 
value; TMB, tumor mutational burden. 
 
 
